The JAK2 V617F mutation in exon 14 is the most common single-point mutation found mainly implicated in chronic myeloproliferative disorders (found in 35% to 95% of PV, ET, and IMF patients) [81, 82]. This evidence concerns the gene JAK2 and essential thrombocythemia.